Abstract #301897


The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.


Back to main JSM 2002 Program page



JSM 2002 Abstract #301897
Activity Number: 291
Type: Contributed
Date/Time: Wednesday, August 14, 2002 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section*
Abstract - #301897
Title: Why Not a Multi-Stage, Single-Arm Phase II Design? Application to Stroke Therapeutics
Author(s): Yuko Palesch*+ and Barbara Tilley
Affiliation(s): Medical University of South Carolina and Medical University of South Carolina
Address: PO Box 250188, Charleston, South Carolina, 29425, USA
Keywords: Phase II clinical trial ; multi-stage design ; stroke ; futility design
Abstract:

In the clinical phase of cancer drug development, open-label, single-arm Phase II clinical trials are conducted to evaluate safety and to assess whether a new agent or procedure shows sufficient efficacy to warrant further studies in the form of large, randomized Phase III clinical trials, i.e., to assess futility. In other clinical areas, this concept of Phase II clinical trials are still relatively novel and under-utilized. Often, they are treated as pilot studies or become under-powered Phase III clinical trials, if conducted at all. Although not all disease areas are amendable to such a design, to illustrate the value of Phase II studies in stroke, we analyzed data from a number of completed Phase III studies as if single-arm, multi-stage Phase II studies were conducted. The results show that for some of these studies, the lack of treatment effect could have been discovered prior to launching a large randomized study, and thereby preventing unnecessary use of resources as well a minimizing exposure of patients to ineffective treatments. We also show that a successful Phase II study (i.e., non-futility) does not guarantee a positive efficacy outcome in Phase III.


  • The address information is for the authors that have a + after their name.
  • Authors who are presenting talks have a * after their name.

Back to the full JSM 2002 program

JSM 2002

For information, contact meetings@amstat.org or phone (703) 684-1221.

If you have questions about the Continuing Education program, please contact the Education Department.

Revised March 2002